Inhibikase Therapeutics, Inc. (IKT) - Dilution Analysis

10-Q filing | 132.0M shares outstanding

10-K filing | 132.0M shares outstanding

10-Q filing | 75.2M shares outstanding

10-Q filing | 74.5M shares outstanding

S-3 filing: The company is filing an S-3 to offer up to $300,000,000 in aggregate principal amount of common stock, preferred stock, and/or debt securities, with $200,000,000 of common stock offered at a price of $1.70 per share.

10-Q filing | 74.3M shares outstanding

10-K filing | 74.3M shares outstanding

S-3 filing: This S-3 filing relates to the resale or other disposition of up to 40,139,474 shares of common stock issuable upon the exercise of Series A-1 Warrants and up to 73,813,529 shares of common stock issuable upon the exercise of Series B-1 Warrants.

S-3/A filing: This S-3/A filing registers for resale up to 58,310,000 shares of common stock and up to 21,985,000 shares of common stock issuable upon the exercise of pre-funded warrants, all held by selling stockholders.

S-3 filing: This prospectus relates to the sale or other disposition from time to time of up to 58,310,000 shares of our common stock, $0.001 par value per share, and up to 21,985,000 shares of our common stock issuable upon the exercise of pre-funded warrants.

10-Q filing | 67.2M shares outstanding

10-Q filing | 7.5M shares outstanding

S-1 filing: S-1 filing for offering up to 4,761,904 shares of Common Stock upon exercise of Private Common Warrants and Inducement Warrants by the Selling Stockholder.

RW filing: Inhibikase Therapeutics, Inc. requests the withdrawal of their registration statement on Form S-1 (File No. 333-278844) because the public offering has been terminated and no securities were sold.

10-Q filing | 6.3M shares outstanding

S-1/A filing: This is an S-1/A filing for a public offering of common stock, pre-funded warrants, and warrants by Inhibikase Therapeutics, Inc.

S-1/A filing: The company is offering shares of common stock together with common warrants, pre-funded warrants and placement agent warrants in a best-efforts offering.

S-1/A filing: The company is offering shares of common stock together with common warrants, pre-funded warrants and placement agent warrants in a best-efforts offering.

S-1/A filing: This S-1/A filing relates to the offering of common stock, pre-funded warrants, common warrants, and placement agent warrants, with Maxim Group LLC as the placement agent, to extend the 201 trial for Risvodetinib (IkT-148009) up to an additional 12 months, support expansion of our biomarker program and ancillary studies required for Phase 3 entry and other general corporate purposes.

S-1 filing: This S-1 filing details a best-efforts offering of common stock, common warrants, pre-funded warrants, and placement agent warrants, with Maxim Group LLC acting as the exclusive placement agent.

10-K filing | 6.5M shares outstanding

10-Q filing | 6.2M shares outstanding

10-Q filing | 5.2M shares outstanding

10-Q filing | 31.1M shares outstanding

10-K filing | 29.0M shares outstanding

POS AM filing: This is an amended filing for common stock issuable upon exercise of warrants, based on 28,977,238 shares of common stock outstanding as of March 14, 2023.

S-1 filing: This S-1 filing includes information about the offering of common stock issuable upon the exercise of warrants, risk factors, and other details about the company's business and financial condition.

10-Q filing | 25.2M shares outstanding

10-Q filing | 25.2M shares outstanding

10-Q filing | 25.2M shares outstanding

10-K filing | 25.2M shares outstanding

S-3 filing: Inhibikase Therapeutics, Inc. may offer and sell, from time to time, up to $100,000,000.00 of its common stock, preferred stock, debt securities, warrants and rights, or any combination of these securities, and/or units consisting of one or more of these securities.

10-Q filing | 25.2M shares outstanding

8-K filing: Dr. Milton Werner, President and CEO of Inhibikase Therapeutics, Inc., entered into a Rule 10b5-1 stock trading plan to sell up to 280,000 shares of the company's stock from January 2022 through January 2024, with 35,000 shares scheduled to be sold each calendar quarter.

10-Q filing | 25.1M shares outstanding

S-1 filing: S-1 filing for common stock offering.

10-Q filing | 10.1M shares outstanding

8-K filing: Inhibikase Therapeutics, Inc. issued 44,143 shares of common stock to Flagship Consulting, Inc. upon conversion of a convertible note at a price of $10.00 per share following the closing of the IPO, and also closed its IPO of 1,800,000 shares of common stock at $10.00 per share and issued a warrant to the underwriter to purchase up to 90,000 shares of common stock at an exercise price of $12.50 per share. ($18.44M proceeds)

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock and warrants. The company intends to use the proceeds from the offering for clinical trials, research and development, and general corporate activities.

S-1/A filing: This is an S-1/A filing for an initial public offering of common stock. The company is offering 1,363,636 shares of common stock at an initial public offering price of $11.00 per share. The company will also issue warrants to the representative of the underwriters as a portion of the underwriting compensation.

S-1/A filing: This S-1/A filing registers for sale 2,272,727 shares of common stock at an initial public offering price of $11.00 per share, and warrants to purchase 113,636 shares of common stock to the underwriter.

S-1/A filing: This S-1/A filing registers for sale 2,272,727 shares of common stock and warrants to purchase 113,636 shares of common stock.

S-1/A filing: This S-1/A filing, dated 2020-09-15, details an offering of 2,272,727 shares of common stock at $11.00 per share, with an underwriter option for an additional 340,909 shares, and also registers warrants to purchase 113,636 shares of common stock for the underwriter.

S-1 filing: This S-1 filing registers an offering of common stock and warrants.